Kalaris Therapeutics Inc. (KLRS)
NASDAQ: KLRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KLRS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $30.47M
- EPS (TTM)
- -$1.84
- Dividend yield
- None
- 52-week range
- 1.25 – 11.88
- Day range
- 1.25 – 1.37
- Volume / Avg
- 37.99K / 77.37K
- Beta
- —
- Shares outstanding
- 23.80M
52-week range
KLRS stock today
Kalaris Therapeutics (KLRS) closed at $1.28 on Nov 20, down 5.19% (-$0.07), versus the S&P 500's 3.70% decline. Trading was light, with 37.99K shares changing hands, about 49% of the average daily volume. At this level, KLRS sits near the bottom of its 52-week range of $1.25 to $11.88: 89.2% below the high, set on Dec 18, 2025 and 2.4% above the low.
KLRS is down 84.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.7%. Kalaris Therapeutics has posted a net loss over the last twelve months (EPS of -$1.84), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kalaris Therapeutics
Company profileKalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Andrew Oxtoby
- Headquarters
- Berkeley Heights, NJ
- Employees
- 20
- IPO year
- 2020
- Website
- kalaristx.com
Financial highlights
Full financialsKalaris Therapeutics reported a net loss of $43.4 million, compared with a loss of $69.2 million a year earlier. Diluted earnings per share came in at -$2.85.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-43.44M | $-69.17M | $-190.42M | $-168.71M | $-171.96M |
| EPS (diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$18.71+1361.72%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.46 vs $-0.51
- Surprise
- +9.80%
KLRS news
All KLRS newsKalaris Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRBUCaribou Biosciences Inc. | 0.2843 | -8.44% | $30.71M | vs KLRS |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs KLRS |
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs KLRS |
| INMBINmune Bio Inc. | 0.827 | -7.50% | $25.60M | vs KLRS |
| TILInstil Bio Inc. | 5.23 | -5.77% | $35.47M | vs KLRS |
| PTHSPelthos Therapeutics Inc. | 6.38 | -8.73% | $25.08M | vs KLRS |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs KLRS |
| MGXMetagenomi Therapeutics Inc. | 0.565 | -7.95% | $21.36M | vs KLRS |
Indexes, lists and sector
Kalaris Therapeutics stock FAQ
What is Kalaris Therapeutics's stock price today?
KLRS last traded at $1.28 as of Nov 20, 4:00 PM EST, down 5.19% on the day. Prices are delayed at least 15 minutes.
Does Kalaris Therapeutics pay a dividend?
No. Kalaris Therapeutics does not currently pay a regular cash dividend.
Who is Kalaris Therapeutics's CEO?
Mr. Andrew Oxtoby is the chief executive officer of Kalaris Therapeutics Inc., which has about 20 employees.
Has KLRS ever split its stock?
Yes. The most recent KLRS stock split was a 1-for-23 split on Jan 16, 2025.
What is the KLRS 52-week high?
The 52-week high for KLRS is $11.88 and the 52-week low is $1.25. The stock is currently 89.2% below its high.